Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-12 6:52 pm Sale |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 3,499,346 10.000% |
-17,505 (-0.50%) |
Filing History |
| 2021-02-12 5:13 pm Purchase |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ORBIMED ADVISORS LLC | 1,711,305 4.890% |
1,076,493 (+169.58%) |
Filing History |
| 2021-02-12 08:14 am Purchase |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 2,800,000 8.000% |
400,000 (+16.67%) |
Filing History |
| 2021-02-11 07:59 am Purchase |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ADAGE CAPITAL PARTNERS GP LLC | 2,450,000 7.000% |
525,000 (+27.27%) |
Filing History |
| 2021-02-08 10:35 am Purchase |
2021-02-05 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 2,625,552 7.499% |
2,625,552 (New Position) |
Filing History |
| 2020-06-22 5:17 pm Purchase |
2020-06-16 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 3,516,851 10.100% |
860,794 (+32.41%) |
Filing History |